New drug aims to shrink liver fat and prevent scarring in fatty liver disease
Disease control
Ongoing
This Phase II trial tests an injection called DR10624 in 110 adults with fatty liver disease (MASLD) who are at high risk of liver fibrosis (scarring). The study is split into two parts: Part 1 checks if the drug reduces liver fat and fibrosis risk, while Part 2 focuses on safety…
Phase: PHASE2 • Sponsor: Zhejiang Doer Biologics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC